20 May 2013
Keywords: AstraZeneca, Brilique, Reimbursement, France, Brilinta
Article | 25 March 2011
Anglo-Swedish drug major AstraZeneca (LSE: AZN) said it has withdrawn a reimbursement application for its potentially blockbuster blood thinner Brilique ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.